Cardiovascular Systems to Webcast Fiscal 2014 First-Quarter Earnings Conference Call Wednesday, October 30

  Cardiovascular Systems to Webcast Fiscal 2014 First-Quarter Earnings
  Conference Call Wednesday, October 30

                 Live Webcast at 3:45 p.m. CT (4:45 p.m. ET)

Business Wire

ST. PAUL, Minn. -- October 23, 2013

Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) will host a live webcast of
its fiscal 2014 first-quarter conference call on Wednesday, Oct. 30, 2013, at
3:45 p.m. CT (4:45 p.m. ET). David Martin, president and chief executive
officer, and Larry Betterley, chief financial officer, will discuss the
company’s results for its fiscal first quarter ended September 30, 2013, CSI’s
recent coronary approval and its financial outlook. The company will issue a
post-market earnings release prior to the call on Oct. 30.

To access the live webcast, go to the investor section of the company’s
website, www.csi360.com, on the day of the conference call and click on the
webcast icon. A webcast replay will be available beginning at 7:45 p.m. CT the
same day.

To participate in the conference call, dial (888) 679-8034 and enter 63886847.
Please dial in at least 10 minutes prior to the call. To pre-register for the
call, log on to the following website:
https://www.theconferencingservice.com/prereg/key.process?key=PTQVDJPXC. When
joining the call, pre-registered participants can enter their PIN code, and
other participants can press *0 to reach the operator, or wait on the line for
operator assistance.

If you do not have access to the Internet and want to listen to an audio
replay of the conference call, dial (888) 286-8010 and enter access number
86279679. The audio replay will be available beginning at 7:45 p.m. CT on
Wednesday, Oct. 30, 2013, through 11 p.m. CT on Wednesday, Nov. 13, 2013.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device
company focused on developing and commercializing innovative solutions for
treating vascular and coronary disease. The company’s Orbital Atherectomy
Systems treat calcified plaque in arterial vessels throughout the leg and
heart in a few minutes of treatment time, and address many of the limitations
associated with existing surgical, catheter and pharmacological treatment
alternatives. The U.S. FDA granted 510(k) clearance for the use of the
Diamondback 360 Orbital Atherectomy System in August 2007. To date, nearly
120,000 of CSI’s devices have been sold to leading institutions across the
United States. In October 2013, the company received FDA approval for the use
of the Diamondback 360 Coronary Orbital Atherectomy System in coronary
arteries. For more information, visit the company’s website at www.csi360.com.

Contact:

Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
investorrelations@csi360.com
or
PadillaCRT
Marian Briggs, 612-455-1742
marian.briggs@padillacrt.com
or
Matt Sullivan, 612-455-1709
matt.sullivan@padillacrt.com